Zafgen Inc. (NASDAQ:ZFGN) Receives Consensus Rating of “Hold” from Analysts
Shares of Zafgen Inc. (NASDAQ:ZFGN) have earned a consensus rating of “Hold” from the nine brokerages that are presently covering the company. Six research analysts have rated the stock with a hold recommendation, two have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $17.54.
A number of equities analysts recently commented on the company. FBR & Co reiterated a “hold” rating on shares of Zafgen in a research note on Tuesday, September 20th. Zacks Investment Research downgraded Zafgen from a “buy” rating to a “hold” rating in a research note on Wednesday, September 21st. Cowen and Company reiterated a “buy” rating and issued a $60.00 price target on shares of Zafgen in a research note on Thursday, August 25th. Canaccord Genuity set a $4.00 price target on Zafgen and gave the stock a “hold” rating in a research note on Thursday, July 21st. Finally, Leerink Swann reiterated a “market perform” rating and issued a $6.00 price target on shares of Zafgen in a research note on Wednesday, July 20th.
Zafgen (NASDAQ:ZFGN) opened at 3.26 on Friday. The stock’s 50 day moving average price is $3.15 and its 200-day moving average price is $5.31. Zafgen has a 52 week low of $2.90 and a 52 week high of $36.09. The stock’s market capitalization is $89.09 million.
In other Zafgen news, CFO Patricia L. Allen purchased 16,000 shares of the business’s stock in a transaction dated Tuesday, July 26th. The shares were bought at an average price of $3.12 per share, with a total value of $49,920.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Thomas E. Hughes purchased 10,000 shares of the business’s stock in a transaction dated Monday, August 29th. The shares were acquired at an average cost of $3.00 per share, for a total transaction of $30,000.00. Following the acquisition, the insider now owns 63,936 shares of the company’s stock, valued at approximately $191,808. The disclosure for this purchase can be found here. Insiders own 20.30% of the company’s stock.
Several large investors have recently added to or reduced their stakes in ZFGN. Alliancebernstein L.P. acquired a new stake in Zafgen during the second quarter worth $114,000. BlackRock Institutional Trust Company N.A. boosted its stake in Zafgen by 23.6% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 503,109 shares of the biopharmaceutical company’s stock worth $3,014,000 after buying an additional 95,945 shares during the period. BlackRock Fund Advisors boosted its stake in Zafgen by 18.3% in the second quarter. BlackRock Fund Advisors now owns 929,566 shares of the biopharmaceutical company’s stock worth $5,568,000 after buying an additional 143,670 shares during the period. BlackRock Investment Management LLC boosted its stake in Zafgen by 51.9% in the second quarter. BlackRock Investment Management LLC now owns 89,327 shares of the biopharmaceutical company’s stock worth $535,000 after buying an additional 30,515 shares during the period. Finally, Vanguard Group Inc. boosted its stake in Zafgen by 18.2% in the second quarter. Vanguard Group Inc. now owns 805,362 shares of the biopharmaceutical company’s stock worth $4,824,000 after buying an additional 123,850 shares during the period. 62.83% of the stock is currently owned by institutional investors.
Zafgen Company Profile
Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.
Receive News & Stock Ratings for Zafgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen Inc. and related stocks with our FREE daily email newsletter.